Home › Funds › BAKER BROS. ADVISORS LP › RCUS
BAKER BROS. ADVISORS LP position in RCUS
ARCUS BIOSCIENCES INC · Health Care
BAKER BROS. ADVISORS LP reported holding 844,816 shares of RCUS (ARCUS BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$26.0M, representing 0.14% of its reported portfolio and ranking #48 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed RCUS holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's RCUS position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in RCUS in Q4 2025 at 270,000 shares (US$6.4M). The position peaked in Q2 2026 at 844,816 shares, worth US$26.0M. Across 3 filings, BAKER BROS. ADVISORS LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 844,816 shares valued at US$26.0M — an increase of 429,195 shares quarter over quarter.. Notable position changes include a 54% increase in Q1 2026 (shares rose 43% over the following quarter), a 103% increase in Q2 2026 (shares fell 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 270.00K | $6.43M | New |
| Q1 2026 | 415.62K | $8.98M | Add |
| Q2 2026 | 844.82K | $26.05M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RCUS and 13F data
RCUS (ARCUS BIOSCIENCES INC) is a Health Care company. 46 other funds we track also report a position in RCUS — the largest reported positions include GILEAD SCIENCES, INC. (US$968.8M), MONTANOVA CAPITAL, LLC (US$147.3M), Siren, L.L.C. (US$74.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RCUS
- GILEAD SCIENCES, INC. 31.42M sh · $968.83M · Q2 2026
- MONTANOVA CAPITAL, LLC 4.78M sh · $147.26M · Q2 2026
- Siren, L.L.C. 2.42M sh · $74.62M · Q2 2026
- SAMLYN CAPITAL, LLC 1.55M sh · $47.70M · Q2 2026
- Soleus Capital Management, L.P. 1.17M sh · $36.03M · Q2 2026
- Sofinnova Investments, Inc. 945.69K sh · $29.16M · Q2 2026
- Parkman Healthcare Partners LLC 919.27K sh · $28.34M · Q2 2026
- Logos Global Management LP 650.00K sh · $20.04M · Q2 2026
- Ikarian Capital, LLC 504.56K sh · $15.56M · Q2 2026
- Decheng Capital LLC 464.78K sh · $14.33M · Q2 2026
- DAFNA Capital Management LLC 441.83K sh · $13.62M · Q2 2026
- Patient Square Capital LP 355.80K sh · $10.97M · Q2 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held RCUS?
BAKER BROS. ADVISORS LP has disclosed RCUS holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is BAKER BROS. ADVISORS LP's current position in RCUS?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 844.82K shares of RCUS (ARCUS BIOSCIENCES INC), valued at $26.05M, representing 0.14% of its reported portfolio and ranking #48.
Has BAKER BROS. ADVISORS LP been buying or selling RCUS?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP increased its position in RCUS. The position peaked in Q2 2026 at 844.82K shares.
Which other funds hold RCUS?
Other major institutional holders of RCUS include GILEAD SCIENCES, INC., MONTANOVA CAPITAL, LLC, Siren, L.L.C., among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.